Sponsored 25 Oct 2016 7 Considerations for Commercializing a New Drug So you have exciting science, but do you know if it will be a commercial success? Ask the drug development and commercialization experts, who have turned the pharma analytics and consultancy industry on its head! We sat down with Mirador Analytics, to talk about bringing a drug from the clinic to the market. They are […] October 25, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 A €103M Target to Reduce Drug Dosage with a Slow-Release Tech Ascendis aims to raise €103M ($112M) for Phase III trials in Growth Hormone Deficiency (GHD) that offer children a weekly alternative to daily injections. After its IPO on NASDAQ last year, the Danish Ascendis is making an underwritten public offering in the US that aims to raise €103M ($112M) to advance its TransCon pipeline. The funds will be directed to […] October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 Here comes the First-ever Combination Therapy for Multiple Sclerosis Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […] October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 The Colours of Biotech: Who’s Doing What in the European Ecosystem in an Infographic Happy Monday! Our colleague, Justine, has put together a wonderful infographic to map out which European biotech companies are making moves in which field, from health to agrotech to medtech. Its vivid colours will surely brighten your day – take a look-see below! Justine is pursuing a PhD at the Heinrich Heine Universität in Düsseldorf after obtaining […] October 24, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2016 Meet the Bioartist that wants to Replace all your Furniture with… Fungi! Can you imagine a future where everything in your daily life is made out of fungi..? It’s actually not such a stretch idea: this bioartist is showing the world all these microorganisms can do. Maurizio Montalti is an artist that uses fungi to build his own furniture and homeware. In 2010, he founded Officina Corpuscoli in Amsterdam […] October 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 New Partnership comes to the Rescue in Neurological Diseases Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and […] October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 It’s time to Modernize Anesthetics! Meet the PAIONeers We travel from Finland back to the heart of Europe to visit the beautiful sights of Aachen. The citizens are starting to turn on the heat and get ready for its famous Christmas markets, while we visit our Biotech of the week, Paion. City: Aachen, Germany Founded: 2000 Employees: 35 Financial Data: €163M market cap + €10M in […] October 21, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease Forget about Madrid and Barcelona, the island of Mallorca has one of the hottest Biotechs in Spain: Sanifit is targeting calciphylaxis, an orphan disease that affects the huge dialysis market. Sanifit received the highest financing round in Spain last year (and probably ever) with €36.6M in series C. With this money, the company is advancing its candidate SNF472 in […] October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 German Record-deal Antiviral drug Succeeds in Phase III AiCuris’ Letermovir succeeds in Phase III after being licensed to MSD in a record €442.5M deal. It acts on a novel CMV target to treat bone marrow transplant infections. AiCuris is a spin-out company from Bayer, Germany’s biggest Pharma, that focuses on developing drugs for infectious diseases. The company licensed its candidate Letermovir (AIC246) to MSD (Merck & co.) in 2012, making it the […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged? Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 Planning a Clinical Trial? Here’s why Data Management matters Data from therapy development, especially those involving cells, can quickly mushroom into an unmanageable pile in the lab — what happens when you move to the clinic? We sat down with Venn Life Sciences to discuss effective strategies in data management that might benefit companies looking to bring a therapy like Tregs to market. Cell […] October 20, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2016 The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies. In May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target […] October 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email